Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Go back to Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer| (NYSE: RCUS) | Delayed: 29.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.73 | 52 Week High | $ | |||
| Open | $29.73 | 52 Week Low | $ | |||
| Day High | $29.73 | P/E | N/A | |||
| Day Low | $29.73 | EPS | $ | |||
| Volume | 1,203 | |||||
| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 14.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.98 | 52 Week High | $19.75 | |||
| Open | $14.98 | 52 Week Low | $4.26 | |||
| Day High | $14.98 | P/E | N/A | |||
| Day Low | $14.98 | EPS | $0.00 | |||
| Volume | 11,418 | |||||
